Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-10-06
1999-01-12
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3174
Patent
active
058589643
ABSTRACT:
Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.
REFERENCES:
patent: 3389550 (1968-06-01), Teitelbaum et al.
Aharoni et al., "T Suppressor Hybridomas and Interleukin-2-Dependent . . . ," Eur. J. Immunol., vol. 23, 17-25, 1993.
Bornstein et al., "Clinical Trails of COP 1 in Multiple Sclerosis," Marcel Dekker, Chapter 22, pp. 469-480 1995.
Fridkis-Hareli et al., "Direct Binding of Myelin Basic Protein and Synthetic . . . ," Proc. Natl. Acad. Sci., vol. 91, pp. 4872-4876, May 1994.c.o.
Jacob et al., "DNA Polymorphism in Cytokine Genes Based on Length . . . ," Immunogenetics, vol. 38, pp. 251-257, 1993.
Johnson, K., "Copolymer I; Positive Results From A Phase III Trial . . . ", American Neurological Association, 200 word abstract, date is not available.
Schlegel et al., "Inhibition of Allorecognition and Prevention of Graft-vs-Host Disease (GVHD) By GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules," 37th Annual Meeting of the America Society of Hematology, Seatle, Washington, Dec. 1-5, 1995, Blood 86 (10 Suppl. 1) 1995 224A, XP00578001.
Schlegel et al., "Prevention of Graft-vs-Host Disease by Peptides Bonding . . . ," Blood, vol. 84, No. 8, pp. 2802-2810, Oct. 15, 1994.
SELA et al., "Suppressive Activity of COP-1 in EAE . . . ," Bull. Inst. Patuer., vol. 88, pp. 303-314, 1990.
Teitelbaum et al., "Suppression of Experimental Allergic Encephalomyelitis . . . ," Eur. J. Immunol., vol. 1, pp. 242-248, 1971.
Teitelbaum et al., "Suppression by Several Synthetic Polypetides . . . ," Eur. J. Immunol., vol. 3, pp. 273-279, 1973.
Teitelbaum et al., "Suppression of Experimental Allergic Encephalomyclitis . . . ," Clinical Immunology and Immunopathology, vol. 3, pp. 256-262, 1974.
Teitelbaum et al., "Suppression of Experimental Allergice Encephalomyelitis . . . ," Israel J. Med. Sci., vol. 13, pp. 1038, 1977.
Teitelbaum et al., "Specific Inhibition of the T-Cell Response . . . ," Proc. Natl. Acad. Sci., vol. 85, pp. 9724-9728, Dec. 1988.
Teitelbaum et al., "Molecular Requirements Involved in Suppression . . . ," Immunochemistry, vol. 13, pp. 333-337, 1976.
Aharoni Rina
Arnon Ruth
Chao Nelson J.
Schlegel Paul G.
Sela Michael
Board of Trustees of the Leland Stanford Junior University
Delaney Patrick R.
Tsang Cecilia J.
Yeda Research and Development Co. Ltd.
LandOfFree
Pharmaceutical compositions comprising synthetic peptide copolym does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising synthetic peptide copolym, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising synthetic peptide copolym will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1515862